The market review of drugs for treating asthma in children
DOI:
https://doi.org/10.24959/sphhcj.17.69Keywords:
analysis of the pharmaceutical market, asthma, manufacturers, dosage forms, INN, assortment of drugsAbstract
Aim. To make a review of the assortment of drugs presented at the pharmaceutical market ofUkraineto treat asthma in children.
Materials and Methods. To achieve the goal the list of drugs for treating asthma in children was analyzed using the information database of the registered medicines presented at the official website of the State Enterprise “State Expert Center of the Ministry of Health of Ukraine”, patient information leaflets, provisions of the Unified clinical protocol of the primary, secondary (specialized) care – Bronchial asthma in children. The study was conducted using statistical, logical and graphical methods.
Results. According to the Unified clinical protocol of the primary, secondary (specialized) care – Bronchial asthma in children and the Ukrainian State Register of Drugs the sample of the drugs under research was formed. This group of drugs was analyzed according to the assortment of dosage forms. Manufacturing countries and pharmaceutical companies presented at the domestic pharmaceutical market of drugs for treating asthma in children were studied. These drugs were structured according to the ATC-classification.
Conclusions. The assortment of drugs for the treatment of asthma in children has been studied; the most common dosage forms have been found. The share of domestic producers and importers of the market segment studied has been determined. Based on the results of the study it has been found that there is the necessity to increase the range of national drugs used for treating asthma in children.References
Глущенко, А. В. Аналітичний огляд сучасних антигістамінних препаратів / А. В. Глущенко // Український медичний альманах. – 2013. – № 3. – С. 187–190.
Здоровье – 21. Основы политики достижения здоровья для всех в Европейском регионе ВОЗ. – Копенгаген: ВОЗ // Европейская серия достижения здоровья для всех. – 1999. – № 8. – 310 с.
Шумна, Т. Є. Формування алергічної патології у дітей Запорізького регіону / Т. Є. Шумна // Запорізький медичний журнал. – 2012. – № 6. – С. 55–58.
Глущенко, О. М. Дослідження використання гомеопатичних лікарських засобів для лікування алергійних захворювань / О. М. Глущенко // Фармацевтичний журнал. – 2014. – № 4. – С. 24–30.
Гудзенко, О. П. Аналіз цінової кон’юнктури вітчизняного ринку протиалергічних препаратів / О. П. Гудзенко, К. І. Козицька // Український медичний альманах. – 2009. – № 5. – С. 63-66.
Богомолов, А. Е. Соціально-економічний тягар алергічних захворювань дихальних шляхів / А. Е. Богомолов // Клінічна імунологія. Алергологія. Інфектологія. – 2015. – № 2. – С. 77–78.
Jarvis, D. The epidemiology of allergic disease / D. Jarvis, P. Burney // MedWeb. – 2002. –№ 2. – P. 52-63.
Нормативно-директивні документи МОЗ України [Електроннийресурс]. – Режим доступу : http://mozdocs.kiev.ua/.
Державний реєстр лікарських засобів [Електронний ресурс]. – Режим доступу : http://www.drlz.com.ua/.
Downloads
Published
Issue
Section
License
Copyright (c) 2017 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).